Background and Purpose-The low-dose (0.6 mg/kg) alteplase strategy to treat acute ischemic stroke patients became widespread in East Asian countries, without rigorous testing against standard-dose (0.9 mg/kg) alteplase treatment.
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September 2015 H emorrhagic transformation is a complication of thrombolytic treatment and may be associated with worse outcome after acute ischemic stroke. 1 Traditionally, East Asian populations have had a higher prevalence of cerebral hemorrhage compared with the Western populations. 2 Concern for hemorrhagic transformation and potentially higher biological activity of alteplase in Asian populations have led to use of lower-dose intravenous (IV) alteplase in this region. 3 A series of single-arm trials conducted in Japan showed that the low-dose alteplase (0.6 mg/kg) was feasible and patients treated with it had similar outcomes to historical controls treated with standard-dose IV tissue-type plasminogen activator (0.9 mg/kg). [4] [5] [6] [7] The low-dose strategy spread rapidly among Asian countries and is estimated to be used in >40% of acute ischemic stroke thrombolysis cases. [8] [9] [10] [11] [12] The efficacy of the low-dose alteplase strategy has been challenged, however, based on a lack of concomitant controls and 2 recent publications from Mainland China and Taiwan, suggesting contrary conclusions in relation to the efficacy of low-dose alteplase. 13, 14 Also, the advent of efficacious and safe endovascular devices and prior use of IV thrombolysis further highlights the need for a safe and effective alteplase strategy. [15] [16] [17] In the absence of a large-scale clinical trial, observational data from a large clinical registry can be useful for assessing alternative treatment strategies. 18 The aim of the current study is to evaluate the comparative effectiveness and safety of low-dose alteplase treatment for acute ischemic stroke patients within 4.5 hours from stroke onset in a prospective, multicenter, clinical stroke registry in South Korea, currently containing 20 000 case records.
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Methods
Study Subjects
Study subjects were selected from a prospective, multicenter, nationwide acute stroke registry database established in April 2008. 20 The collaborative registry study group consisted of 15 academic and regional stroke centers as of July 2014. Registrars at participating centers enrolled consecutive acute stroke cases admitted within 7 days from onset into a web-based database system. Study data were regularly audited by the central adjudication committee using prespecified query sequences. The overall study protocol was approved by the ethics committee of each participating center.
Data analysis was performed for study subjects who met the following criteria: (1) acute stroke patients who were admitted between November 2009 and May 2013 (N=15 815); (2) those who had relevant ischemic lesions documented by neuroimaging studies (N=14 284); (3) those who arrived within 4.5 hours from stroke onset (N=4123); and (4) those who received IV tissue plasminogen activator (N=1614). A total of 94 cases were removed from the analytic data set because of missing information regarding the dose of alteplase (N=6), occurrence of symptomatic hemorrhagic transformation (SHT; N=8), modified Rankin Scale (mRS) score at 3 months after stroke onset (N=34), or those who treated after ≥4.5 hours from symptom onset (N=46). Acute stroke management, including recanalization therapy, was performed according to the current clinical guidelines and institutional protocols and at the discretion of individual physicians who managed the patients. 21 Information on patient characteristics and treatments were obtained from the registry database. The definition of collected clinical information is described in Methods in the online-only Data Supplement.
Study Outcomes
The primary outcome measures were a favorable functional outcome (mRS score 0-1) at 3 months and occurrence of SHT. mRS scores were prospectively collected at a telephone interview or a clinic visit by certified registrars. SHT was defined as a cerebral hemorrhage documented by neuroimaging study and accompanied by an increase of ≥4 points on the National Institute of Health Stroke Scale (NIHSS) score compared with the baseline score or from the lowest NIHSS score in the individual subject before the development of SHT. Secondary outcome measures were mRS score 0 to 2 at 3 months and mortality at 3 months.
Statistical Analysis
The characteristics of the low-dose alteplase group were expected to substantially differ from those of the standard-dose group. Missing values were found in 0.4% of the final analysis data set and imputed through multivariate sequential regression models to generate a single imputed data set.
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To generate a comparable data set, we calculated a propensity score to estimate the individual probability of a patient receiving low-dose alteplase rather than standard-dose treatment.
23 Thirty-one variables were used as covariates to calculate propensity scores (cstatistics =0.787, a P value of Hosmer-Lemeshow test <0.001). The inverse probability of treatment weighting (IPTW) was used as a primary strategy to adjust for baseline imbalances. 24 The conventional matching strategy was also applied. Data balancing was examined using an absolute standardized difference in covariate means. 25 The distributions of baseline covariates were fairly well balanced by applying propensity scores; the absolute standardized differences after IPTW were within the margin of 0.1, except for the delay from onset to arrival, which had to be included in the multivariable model (Table  I and Figures I and II in the online-only Data Supplement) .
The effectiveness and safety of the IV treatment of low-dose alteplase versus the standard-dose alteplase were tested through multivariable logistic regression models, accounting for the cluster effect, applying IPTW with further adjustment for disproportionate covariates (absolute standardized difference >0.10 after applying propensity score techniques) and variables predetermined based on their influences on outcomes and treatment grouping. To address variation of alteplase dosage across centers, a generalized linear mixed model was used by treating center effect as a random intercept. In the IPTW analysis, a stabilized weight was used not only to maintain number of subjects used in the weighted analysis the same as the unweighted one, but also to yield more efficient interval estimates having closer to 95% coverage probabilities. 26 As sensitivity analysis, a conventional binary logistic model, a logistic model accounting for the cluster effect without propensity-weighting, and a propensity score matching model were also performed and presented. We also made a prespecified subgroup analysis by excluding patients receiving endovascular treatment. Details of statistical methods are presented in Methods in the online-only Data Supplement.
Significance levels were set at a 2-tailed P value <0.05. Statistical analyses were performed by biostatisticians (J.S. Lee and J. Lee) using SAS 9.3 (SAS Institute, Cary, NC).
Assuming that (1) a 40% of patients receiving alteplase were treated with the low-dose strategy, (2) the proportion of the mRS 0 to 1 at 3 months in the standard-dose group was 40%, and (3) the clinically acceptable difference in the mRS 0 to 1 at 3 months (the low-dose group minus the standard-dose group) was −7%, a sample of 1220 patients (488 for the low-dose group and 732 for the standard-dose group patients in each group) were required to provide a power of 80% with a one-sided significance level of 0.05. Assuming a 7% of prevalence of missing information for important covariates and outcome variables, it was targeted to collect a total of 1312 subjects.
Results
Between November 2009 and March 2013, 1526 acute ischemic stroke cases who met the eligibility criteria were selected from a total of 15 815 registered stroke patients. 
Stroke
September 2015
Average baseline NIHSS score was 11.5±6.5 points, and the delay from onset to IV alteplase injection was 2.1±0.9 hours. Endovascular recanalization treatment was performed in 26.5% of cases (n=404). A favorable outcome (mRS score 0-1) at 3 months after stroke was achieved in 34.5% of subjects (n=526), and SHT occurred in 7.0% (n=107). Low-dose alteplase was used in 29.5% (n=450) of the patients. Compared with the standard-dose group, patients who received low-dose alteplase were more likely to be female, arrive earlier, present with a higher NIHSS score, and have cardioembolic stroke, hypertension, and atrial fibrillation (Table) . Low-dose alteplase was more frequently used in patients who had endovascular treatment. The proportion of low-dose alteplase usage in the study population varied widely across centers, ranging from 0% to 96.5%, but it was not related to the center's characteristics, such as monthly cases of ischemic stroke or recanalization treatment (Figure 1 ).
The distribution of mRS scores at 3 month was statistically different by the alteplase dose, without noticeable shift of main outcome indices toward a particular group (Figure 2) . Analysis of propensity-weighting data set accounting for a cluster effect from treating centers showed that the adjusted odds ratios and the 95% confidence interval of the low-dose strategy were comparable for the proportions of achieving mRS score 0 to 1 at 3 months (adjusted We selected 1076 patients from the main data set who did not receive endovascular recanalization treatment. In this subgroup data set, the low-dose alteplase was used in 18.5% (n=207) of the cases, and the distribution of covariates was different between those receiving low-dose alteplase and those receiving standard-dose alteplase (Table II in the online-only Data Supplement). A separate set of propensity scores was calculated, and baseline imbalances were adjusted through IPTW and propensity score matching (Table III and  Figures III 
Discussion
Our study shows that the alternative low-dose alteplase strategy has comparable effectiveness and safety when compared with the standard-dose regimen to treat acute ischemic stroke patients within 4.5 hours from onset.
The adjusted frequency of achieving an mRS score 0 to 1 at 3 months after stroke onset was 36% in the low-dose alteplase group and 32% in the standard-dose group. These results were similar to the low-dose trials from Japan, as well as the standard-dose trial from the United States, where beneficial results ranged from 33% to 39%. 1, 4, 7 Likewise, our outcomes were comparable to the real-world registry data of low-dose alteplase from Japan and that of the standard-dose strategy from an international registry. 6 ,28 Therefore, our results from a real-world clinical practice setting were quite similar to historical data.
Although most guidelines recommend 0.9 mg/kg alteplase, it is not uncommon, from the authors' experience, to deviate from the guidelines in South Korea. Low-dose alteplase would be favored when patients are thought to be at high risk of bleeding, such as in older patients, those with decreased renal function, or when endovascular treatment is anticipated. Furthermore, even if 0.6 mg/kg alteplase was administered according to institutional protocols, a supplemental dose of 0.3 mg/kg was occasionally given when a neuro-interventionist was not available.
There are dozens of papers regarding this controversy; however, the data or analyses have been incomplete and have held back the low-dose alteplase strategy from more 
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September 2015 potential widespread use. Recently, 2 reports from Chinese studies addressed the pitfalls by analyzing fairly large registry data. 13, 14 However, both of the studies did not include prespecified doses of IV alteplase, and variation in the dose of alteplase among centers and patients was substantial. The analyses were subject to casual post hoc grouping of alteplase doses, and thus, it is difficult to draw any conclusions based on proper comparison. In the current analysis, we applied propensity score analysis methods to ensure maximal comparability between the 2 groups and tried to answer causal inference issues. We also adapted generalized mixed models to account for a random effect from inevitable clustering of cases by treating centers because detailed in-hospital management protocols and logistics of hyperacute stroke cases may vary according to the centers and which may affect patients' outcome.
Would the low-dose alteplase strategy have gained a firm ground, it could be a practical option at least for ischemic stroke patients of East Asian ancestry who are expected to have a higher risk of cerebral hemorrhages than Western populations. 2 Decreased exposure of alteplase may mitigate systemic complications, including bleeding. Safety would be a bigger concern in the era of recently proven endovascular strategy. The cost of alteplase is still a barrier in implementing acute thrombolysis in low-income countries. 10 Until now, even in the participating centers of this study, as shown in Figure 1 , doubt and reluctance on the low-dose strategy is roaming over. Our data, and the ongoing clinical trial, may settle the current dispute in near future. 29 Unexpectedly, we found a discrepancy in 3-month mortality between the low-dose and standard-dose alteplase groups in statistical models, which has not been published. Alteplase has been reported to have experimental neurotoxicity and may augment inflammatory reaction around infarcted tissue. 30 Thus, it is possible that higher-dose alteplase (0.9 mg/kg) regimen could cause additional tissue injury or parenchymal edema in ischemic stroke patients. Decreased bleeding events outside of the brain could be another explanation; however, we do not have such information in our data set. This mortality effect should be further analyzed and discussed when the results of the ongoing clinical trial become available.
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A few points may require further clarification. Detailed protocols and logistics may differ in each hospital. Although we tried to take into account such variability by introducing a random intercept effect with mixed models, unmeasured confounding may still exist. The authors made a preplanned subgroup analysis of IV-only cases to address this point using a separate set of propensity scores. Direct comparison of results from the main and subgroup analyses may not be appropriate, but the directions of associations were retained. We tried to overcome the inevitable imbalances between the 2 alteplase dose groups by using propensity score techniques, but possibilities of residual and unmeasured confounding still exist. We could not exclude a possibility that most of neutral results in the comparisons between the low-dose versus standard-dose strategies might result from that this study was underpowered to detect the difference between them. This analysis was based on an observational registry, and our results should be confirmed by future researches. Finally, contrary to our expectations, this study did not support that the low-dose alteplase leads to a decrease of SHT. Unmeasured confounders related to higher bleeding risk to make treating physicians choose the low-dose strategy might be considered as an explanation.
Our results show that the low-dose alteplase of 0.6 mg/ kg would be a practical alternative for populations at a higher bleeding risk, such as East Asians, or for patients who are eligible for endovascular treatment.
31 Furthermore, as suggested previously, 32 the low-dose strategy might benefit patients other than the East Asians. However, our study is not conclusive because our data set was underpowered, lacked fully supporting theoretical mechanism, and had methodological limitation. Therefore, additional confirmation in randomized controlled trials will be useful. 
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Definitions of collected clinical information
Locations of occluded arteries were determined using computed tomography angiography, magnetic resonance angiography, or transfemoral cerebral angiography taken before initiation of any recanalization treatment. If unavoidable, location was determined based on angiography images taken immediately after infusion of intravenous thrombolytic agents. Location of occluded arteries was categorized into carotid artery (common carotid artery to intracranial internal carotid artery), middle cerebral artery, other cerebral arteries (vertebrobasilar artery, posterior cerebral artery, anterior cerebral artery or simultaneous occlusion of multiple major arteries) or no occlusion in major arteries. In unusual situations, endovascular treatment (EVT) was performed in smaller arteries such as posterior inferior cerebellar artery and such cases were included in the no occlusion in major arteries. Hypertension was defined as systolic blood pressure ≥140 mm Hg after stabilization of neurological and medical condition, or history of taking blood pressure lowering medication before stroke. 1 Diabetes was defined as previous diagnosis of type I or II diabetes, fasting blood glucose ≥126 mg/dL, or Hb A1c level ≥6.5%. 2 Dyslipidemia was defined as a fasting serum total cholesterol ≥240 mg/dL, a fasting low-density lipoprotein level ≥160 mg/dL, or previous diagnosis of dyslipidemia with current use of lipid-lowering medications. 3 Time points were defined as following; onset as last seen normal, and treatment were infusion of intravenous thrombolytic agents for intravenous-only thrombolysis.
Calculation of required sample size
The proportion of low-dose alteplase cases in the CRCS-5 registry was approximately 40%. 4 Level of significance was set as one-sided alpha 0.05 level, and power was set as 0.80 level. The primary efficacy outcome (modified Rankin Scale score 0 -1 at 3 months after stroke) was supposed to occur in 40% of the standard treatment group, 5, 6 and 40% in the low-dose alteplase group. 7, 8 Clinically acceptable delta for the low-dose alteplase group was supposed to be -0.07. This value was derived from the half the number of the difference (0.14) between tPA-treated and placebo-treated groups for the identical outcome indicator of the NINDS rt-PA trial. 6 From the above assumption, the required sample size was 1220 (488 cases for the low-dose alteplase group and 732 cases for the standard-dose alteplase group). The prevalence of missing information for the main exposure and major outcome variables was supposed to be 7%, and therefore the final sample size for the current study was estimated to be 1312.
Statistical methods and propensity score analyses
Summary statistics were presented as means ± standard deviations (SDs) or frequencies (percentages), as appropriate. The baseline characteristics of the low-dose alteplase group and standard-dose alteplase group were compared using Pearson's chi-squared test for categorical variables and Student's t test for continuous variables. The frequency of missing data was 380 cells (0.5%), ranging from 0.1% in systolic or diastolic blood pressure to 6.6% for high-density lipoprotein cholesterol. To avoid loss of data, multivariate sequential regression models were used to generate a single imputed dataset. 9 The characteristics of the low-dose alteplase group were expected to substantially differ from those of the standard-dose group. To control for baseline imbalances and generate a comparable dataset, we calculated a propensity score to estimate the individual probability of a patient receiving low-dose alteplase rather than standard-dose treatment. 10 Thirty one variables were used as covariates to calculated the propensity score, including sex, age, time between onset to arrival, time between onset to alteplase infusion, stroke subtype according to the Trial of Org 10172 in Acute Stroke Treatment classification with some modifications, 11 NIHSS score at arrival, pre-stroke mRS score, body-mass index, hypertension, diabetes, dyslipidemia, ever-smoking, atrial fibrillation, pre-stroke antiplatelet use, pre-stroke anticoagulant use, location of arterial occlusions, white blood cell counts, total cholesterol level, blood urea nitrogen, creatinine, hemoglobin, triglyceride, hematocrit, high-density lipoprotein cholesterol, random glucose level at arrival, platelet count, prothrombin time, systolic blood pressure at arrival, diastolic blood pressure at arrival, onset-to-treatment delay, and endovascular recanalization treatment. The propensity scores for individual cases were estimated through multivariable logistic regression models taking dose of intravenous alteplase (standard-dose as a reference category) as a dependent variable and the aforementioned 31 variables as independent variables. P-value from Hosmer-Lemeshow goodness of fit test was <0.001 and the area-under-the-curve was 0.787.
Data balancing was checked using the absolute standardized difference in covariate means (ASD). Absolute standardized differences in means (ASD) of covariates were calculated before and after the application of IPTW and propensity score matching. The distributions of baseline covariates were fairly well balanced by applying propensity scores; the ASDs after IPTW were within the margin of 0.1 except for the delay from onset to arrival, which had to be included in the multivariable model, as displayed in the Supplemental data.
The effectiveness and safety of the intravenous treatment of low-dose alteplase versus the standard-dose alteplase were tested through multivariable logistic regression models, accounting for the cluster effect, applying IPTW with further adjustment for disproportionate covariates (ASD >0.10 after applying propensity score techniques) and variables predetermined based on their influences on outcomes and treatment grouping. 12 To address variation of alteplase dosage across centers, a generalized linear mixed model was employed treating center effect as a random intercept. In the IPTW analysis, a stabilized weight was used not only to maintain number of subjects used in the weighted analysis being same as the unweighted one but also to yield more efficient interval estimates having closer to 95% coverage probabilities. Each model was tested with further adjustment for disproportionate covariates whose ASDs were >0.10 even after applying propensity score techniques and predetermined clinically relevant variables (age, sex, NIHSS score at arrival, onset-to-treatment delay and endovascular treatment). Additional adjustments for clinically relevant covariates, all of which are assumed to have substantial influence on the outcomes, were introduced to more effectively reduce residual confounding with heightened precision. 13 In relation to sensitivity analysis, a conventional binary logistic model, a logistic model accounting for the cluster effect without propensity score techniques, IPTW models without cluster effect of centers, and a propensity score matching model were also performed. The cluster effect of treating center was addressed using a generalized linear mixed model with a separate set of adjusting covariates. Cluster effects was not considered in the matching models due to clusters should be broken out, as there a few centers with only a few cases were included in the dataset.
A prespecified subgroup analysis was planned to evaluate the effectiveness of intravenous low-dose alteplase injection in IV-only cases without endovascular treatments. A set of separate propensity scores for those receiving low-dose alteplase treatment was calculated from an identical set of covariates except for the endovascular treatment. P-value from Hosmer-Lemeshow goodness of fit test was 0.0568 and the area-under-the-curve was 0.678 .Imbalances between the low-dose and standard-dose groups before and after IPTW and propensity score matching were also analyzed, and the effectiveness of low-dose alteplase was examined using multivariable logistic regression models additionally adjusted for disproportionate covariates (ASD >0.10) after applying propensity score techniques and predetermined clinically relevant variables like the main analysis except for endovascular treatment. Random intercepts for the cluster effects were estimated except in a model for symptomatic hemorrhagic transformation in the subgroup of intravenous-only patients. Therefore, the association between symptomatic hemorrhagic transformation and the dose of alteplase had to be estimated without random intercept effects.
Significance levels were set at a two-tailed P <0.05. Statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC) by experienced biostatisticians (JS Lee and J Lee).
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IPTW, inverse probability of treatment weighting; PS, propensity score; ASD, absolute standardized differences in means; NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin Scale Values are number of patients (percentages) or means ± standard deviations
Supplemental Figures
Supplemental Figure I . Absolute standardized differences in means of 31 covariates for estimating propensity score before and after propensity score weighting in the whole subjects.
Supplemental Figure II . Absolute standardized differences in means of 31 covariates for estimating propensity score before and after propensity score matching in the whole subjects.
Supplemental Figure III . Absolute standardized differences in means of 30 covariates (except endovascular recanalization treatment) for estimating propensity score before and after propensity score weighting in intravenous-only subjects.
